Tango Therapeutics (TNGX) Common Equity (2020 - 2026)

Tango Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $391.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 134.78% year-over-year to $391.5 million in Q1 2026; TTM through Mar 2026 was $391.5 million, a 134.78% increase from a year earlier, with the FY2025 full-year figure at $346.2 million, up 73.51% from the prior year.
• Common Equity advanced to $391.5 million in Q1 2026 per TNGX's latest filing, from $346.2 million in the prior quarter.
• Across five years, Common Equity topped out at $391.5 million in Q1 2026 and bottomed at $135.0 million in Q2 2025.
• The 5-year median for Common Equity is $249.5 million (2022), against an average of $250.1 million.
• Across the five-year window, Common Equity jumped 453.38% in 2022 and sank 45.51% in 2025, its largest moves.
• Year by year, Common Equity stood at $249.5 million in 2022, then increased by 1.46% to $253.1 million in 2023, then retreated by 21.17% to $199.5 million in 2024, then surged by 73.51% to $346.2 million in 2025, then grew by 13.09% to $391.5 million in 2026.
• Per Business Quant, the three latest TNGX Common Equity figures stand at $391.5 million (Q1 2026), $346.2 million (Q4 2025), and $160.0 million (Q3 2025).